Polymers in nephrology: Characteristics and needs

International Journal of Artificial Organs

Volumn 25, Issue 5, 2002, Pages 470-479

  Vienken, Joerg ^a  

^a FRESENIUS MEDICAL CARE   (Germany)

Author keywords

Biocompatibility; Dialysis; Polymers; Residuals

Indexed keywords

BLOOD; CHEMICAL ACTIVATION; CONTROLLED DRUG DELIVERY; DIALYSIS; DIALYSIS MEMBRANES; DRUG INTERACTIONS; FUNCTIONAL POLYMERS; MEDICAL APPLICATIONS; PROTEINS; TARGETED DRUG DELIVERY; TUBING;

ADSORBERS; CAPILLARY MEMBRANES; EXTRACORPOREAL CIRCUITS; HEMOPERFUSION; HIGH PURITY; IMMUNOADSORPTION; PERFORMANCE PROPERTIES; POLYMER BACKBONES; PROTEIN ADSORPTION; RESIDUAL;

BIOCOMPATIBILITY;

3,4 METHYLENEDIOXYAMPHETAMINE; BIOMATERIAL; BRADYKININ; CELLULOSE; CHEMOSTERILANT; COMPLEMENT; CUPROPHANE; DIETHYLAMINOETHYL CELLULOSE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG; ETHYLENE OXIDE; FLUOROCARBON; KININOGEN; OLIGOMER; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; POLYAMIDE; POLYCARBONATE; POLYETHER DERIVATIVE; POLYETHERURETHAN; POLYMER; POLYPROPYLENE; POLYSULFONE; POLYURETHAN; POLYVINYLCHLORIDE; POVIDONE; PREKALLIKREIN; PROTEIN; SULFONIC ACID DERIVATIVE;

ADSORPTION; ANAPHYLAXIS; ARTIFICIAL ORGAN; BIOCOMPATIBILITY; BIODEGRADATION; BLOOD CLOTTING; BLOOD COMPATIBILITY; BODY FLUID; CELL ACTIVATION; CHRONIC DISEASE; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; DIALYSIS; DIALYSIS MEMBRANE; EQUIPMENT DESIGN; EXPERIMENTAL MODEL; EXTRACORPOREAL CIRCULATION; GOOD MANUFACTURING PRACTICE; HEMOPERFUSION; HISTOCOMPATIBILITY; HUMAN; IMMUNOADSORPTION; INFLAMMATION; INSTRUMENT STERILIZATION; INTOXICATION; KIDNEY FAILURE; LONG TERM CARE; MATERIALS; NEPHROLOGY; NONHUMAN; PLASMAPHERESIS; THERMOSTABILITY;

EID: 0036587489     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880202500518     Document Type: Conference Paper

References (50)

1. Hench L. Biomaterials. Science 1980; 208: 826-31.
2. Bandel W. Entwicklungen auf dem Cuprophan-Membran- und Hohlfaser-Gebiet Mitt. AG für Klin Nephrologie 1975; 4: 29-47.
3. Henne W, Dünweg G, Bandel W. Hollow fibre dialysis membrane. UK-Pat. Appl. GB 2 090 187, 07.07.1982.
4. Baurmeister U, Brodowski W, Diamantoglou M, et al. Dialysemembran mit verbesserter Biokompatibilität. German Patent, DE OS 3 1985; 524-96.
5. AKZO Faser AG. Hemophan, a modified membrane for dialysis US-Patent No. 4,668,396; European Patent No. 172, 497 (1987).
6. Diamantoglou M, Lemke H, Vienken J. Cellulose ester as membrane material for hemodialysis. Int J Artif Organs 1994; 17: 385-91.
7. Diamantoglou M, Platz J, Vienken J. Cellulose-carbamates and derivatives as membrane materials for hemodialysis. Artif Organs 1999; 23: 15-23.
8. Buck R, Göhl H. A permselective asymmetric membrane suitable for a hemodialysis and a process for manufacturing membranes. European Patent 1988; 305-587.
9. Sluma H, Passlack J, Buttner B, Scherf M. Synthetic hydrophilic membranes and method of their manufacture. German Patent DE 4 112 508, 17.04 (1991).
10. Streicher E, Schneider H. Polysulphone membrane mimicking human glomerular basement membrane. Lancet 1983; ii: 1136.
11. Göhl H, Konstantin P, Gullberg C. Hemofiltration membranes. Contrib Nephrol 1982; 32: 20-30.
12. Vienken J, Diamantoglou M, Kamusewitz H, Paul D. Considerations on developmental aspects of biocompatible membranes. Artif Organs 1995; 19: 398-406.
13. Clark W, Shinaberger J. Clinical evaluation of a new high-efficiency hemodialyser: polysynthane. ASAIO J 2000; 46: 288-92.
14. Sasaki M, Hosoya N, Saruhashi M. Development of a vitamin E-bonded membrane. Contrib Nephrol 1999; 127: 49-70.
15. Center for Devices and Radiological Health, US Food & Drug Administration Safety assessment of Di(2-ethylhexyl)phthalate (DEHP) released from medical devices; From September 07, 2001
16. Klinkmann H, Davison A. The biocompatibility puzzle, partly solved, partly enigmatic. Nephrol Dial Transplant 1994; 9 (suppl 2): S187-6.
17. ANSI/AAMI/ISO 10993-4 (1993) Biological evaluation of medical devices, Part 4. Selection of tests for interactions with blood, p.3.
18. Basmadjian D, Sefton M. Coagulation on biomaterials in flowing blood: some theoretical considerations. Biomaterials 1997; 18: 1511-22.
19. Klinkmann H, Davison A, editors. Consensus Conference on Biocompatibility. Nephrol Dial Transplant 1994; 9 (suppl 2): S1-186.
20. Cornelius R, Brash J. Identification of proteins adsorbed to hemodialyser membranes from heparinized blood. J Biomater Sci Polym Ed 1993; 4: 291-304.
21. Morti S, Zydney A. Protein-membrane interactions during hemodialysis: effects on solute transport. ASAIO J 1998; 44: 319-26.
22. Tielemanns C, Madoun P, Lenaers M, Schandene L, Goldman M, Vanherweghem J. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE-inhibitors. Kidney Int 1990; 38: 982-4.
23. Parnes E, Shapiro W. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyser. Kidney Int 1991; 40: 1148-52.
24. Brunet P, Jaber K, Berland Y, Baz M, Anaphylactoid reactions during hemodialysis and hemofiltration: role of associating AN69 membrane and angiotensin-converting enzyme. Am J Kidney Dis 1992; 19: 444-447.
25. Petrie J, Campbell Y, Hawley C, Hogan P. Anaphylactoid reactions in patients on hemodialysis with AN69 membranes whilst receiving ACE-inhibitors. Clin Nephrol 1991; 36: 264-5.
26. Schaefer R, Fink, E, Schaefer L, Barkhausen R, Kulzer P, Heidland. A Role of bradykinin in anaphylactoid reactions during hemodialysis with AN69 dialysers. Am J Nephrol 1993; 13; 473-7.
27. Kammerl M, Schaefer R, Schweda F, Schreiber M, Riegger G, Kramer B. Extracorporeal therapy with AN69 membranes in combination with ACE-inhibition causing severe anaphylactoid reactions: still a current problem? Clin Nephrol 2000; 53: 486-8.
28. Mannstadt M, Touam M, Fink E, et al. No generation of bradykinin with a new membrane (SPAN) in hemodialysis patients treated with ACE-inhibitors. Nephrol Dial Transplant 1995; 10: 1696-700.
29. Kojima S, Harada-Shiba M, Nomura S, et al. Effect of nafamostat mesilate on bradykinin generation during LDL-apheresis using a dextran sulfate cellulose column. Trans ASAIO 1991; 37: 644-648.
30. Van der Kamp K, von Oeveren W. Factor XII-fragment and kallikrein generation in plasma during incubation with bio-materials. J Biomed Mater Res 1994; 28: 349-52.
31. Matata B, War S, Sundaram S, et al. In vitro contact phase activation with hemodialysis membranes: role of pharmaceutical agents. Biomaterials 1995; 16: 1305-12.
32. Pegues D, Beck-Sague C, Wollen S, et al. Anaphylactoid reactions associated with reuse of hollow-fiber hemodialysers and ACE-inhibitors. Kidney Int 1992; 42: 1232-7.
33. Coppo R, Amore A, Cirina P, et al. Bradykinin and nitric oxide generation by dialysis membranes can be blunted by alkaline rinsing solutions Kidney Int 2000; 58: 881-8.
34. Werner C, Jacobasch H. Surface characterisation of polymers for medical devices. Int J Artif Organs 1999; 22: 160-76.
35. Nakai S and the Patient Registration Committee of the Japanese Society for Dialysis Therapy. An overview of dialysis treatment in Japan. J Jpn Soc Dial Ther 2001; 34: 1121-47.
36. Mettang T. The fate of leached DEHP in patients undergoing CAPD. Perit Dial Int 1996; 16: 58-62.
37. Dolovich J, Bell B. Allergy to products of ethylene oxide gas. J Allergy Clin Immunol 1978; 62: 30-2.
38. Grammer L, Patterson R. IgE against ethelyne oxide-altered human serum albumin as an etiologic agent in allergic reactions of hemodialysis patients. Artif Organs 1987; 11: 97-9.
39. Handlos H. Hazards of ethylene oxide sterilisation Proc. Concept Symposium 3/81 on sterilisation procedures. Heildeberg 1981, pp. 90-2.
40. Takesawa S, Satoh S, Hidai H, Sekiguchi M, Sakai K. Degradation by gamma irradiation of regenerated cellulose membranes for clinical dialysis. Trans ASAIO 1987; 33: 584-7.
41. Bommer J, Miltenburger H, Hoerner V, Kilian S. Cytotoxicity of gray sterilized dialysis devices (abstract). J Am Soc Nephrol 1994; 5: 408.
42. Shintani H, Nakamura A. Analysis of a carcinogen, 4,4′methylenedianiline, from thermosetting polyurethane during sterilisation. J Anal Toxicol 1989; 13: 354-7.
43. Mazzu A, Smith C. Determination of extractable methylene dianiline in thermoplastic polyurethanes by HPLC. J Biomed Mater Res 1984; 18: 961-8.
44. Hennig E, John A, Zartnack F, et al: Biostability of polyurethanes. Int J Artif Organs 1988; 11: 416-27.
45. Hutter J, Kuehnert M, Wallis R, Lucas A, Sen S, Jarvis W. Acute onset of decreased vision and hearing traced to hemodialysis treatment with aged dialysers. JAMA 2000; 283; 2128-34.
46. Oba T, Tsuji K, Nakamura A, et al. Migration of acetylated hemicellulose from capillary hemodialyser to blood, causing scleritis and/or iritis. Artif Organs 1984; 8: 429-35.
47. Averbukh Z, Modai D, Sandbank J, et al. Red eye syndrome: clinical and experimental experience in a new aspect of diffuse eosinophilic infiltration. Artif Organs 2001; 25: 437-40.
48. Ferriman A. Baxter identifies processing fluid as possible cause of deaths. Br Med J 20001; 323: 1088.
49. Sass D, Russel A, van Dyke A, Wood E, Johnson S, Didisheim P. Gas embolism due to intravenous FC80 liquid fluorocarbon. J Appl Physiol 1976; 40: 745-51.
50. Henderson L. Dialysis in the 21st century. Am J Kidney Dis 1996; 28: 951-7.